Acquisitions, Investments, and Licenses - Schedule of Purchase Price Allocation (Details) - USD ($) $ in Thousands		Jun. 30, 2015	May. 05, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	[1]	$ 289,607		$ 224,292
EirGen Pharma Ltd
Business Acquisition [Line Items]
Current assets	[2]		$ 11,795
Intangible assets			57,671
Goodwill			66,823
Property, plant and equipment			8,117
Other assets			1,232
Accounts payable and other liabilities			(6,254)
Deferred tax liability			(5,618)
Total purchase price			133,766
Cash			5,500
Accounts receivables			2,700
Inventory			2,200
Other assets			1,400
IPR&D assets | EirGen Pharma Ltd
Business Acquisition [Line Items]
Intangible assets			19,597
Customer relationships | EirGen Pharma Ltd
Business Acquisition [Line Items]
Intangible assets			34,155
Currently marketed products | EirGen Pharma Ltd
Business Acquisition [Line Items]
Intangible assets			$ 3,919

[1] As of June 30, 2015 and December 31, 2014, total assets include $7.1 million and $7.6 million, respectively, and total liabilities include $12.7 million and $12.1 million, respectively, related to SciVac Ltd (“SciVac”), now known as SciVac Therapeutics, Inc., a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.

[2] Current assets include cash, accounts receivable, inventory and other assets of $5.5 million, $2.7 million, $2.2 million and $1.4 million, respectively, related to the EirGen acquisition. The fair value of the accounts receivable equals the gross contractual amount at the date of acquisition.